I've found this white paper very interesting, particularly in light of Marco's recent appointment.
https://www.iqvia.com/-/media/library/white-papers/emerging-markets-four-entry-strategies-for-small.pdf?vs=1
It has been written specifically for small and mid-sized pharma companies entering emerging markets - but it's got a lot of relevance for where PAR goes from here, and the potential pros and cons of each option available.
research reports and media, page-2819
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
19.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $70.04M | |||
| Open | High | Low | Value | Volume |
| 20.0¢ | 20.5¢ | 19.5¢ | $39.95K | 199.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 10 | 192539 | 19.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 20.0¢ | 164484 | 6 |
View Market Depth
| Last trade - 11.29am 09/10/2024 (20 minute delay) ? |
| PAR (ASX) Chart |